Literature DB >> 646016

Protective immunity to Naegleria fowleri in experimental amebic meningoencephalitis.

Y H Thong, C Shepherd, A Ferrante, B Rowan-Kelly.   

Abstract

Naegleria fowleri, a free-living ameboflagellate, is the causative organism of primary amebic meningoencephalitis. Intranasal inoculation of N. fowleri in mice produces an infection similar to human disease. Mice immunized with live N. fowleri by intraperitoneal injection were found to be more resistant to subsequent intranasal challenge. These results may provide a lead to the development of immunotherapy for this virulent disease for which satisfactory chemotherapy is presently unavailable.

Entities:  

Mesh:

Year:  1978        PMID: 646016     DOI: 10.4269/ajtmh.1978.27.238

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

1.  Immunity to pathogenic free-living amoebae: role of cell-mediated immunity.

Authors:  R T Cursons; T J Brown; E A Keys; K M Moriarty; D Till
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

2.  Human neutrophils require activation by mononuclear leucocyte conditioned medium to kill the pathogenic free-living amoeba, Naegleria fowleri.

Authors:  A Ferrante; T J Mocatta
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

3.  Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri.

Authors:  Jong-Hyun Kim; Hae-Jin Sohn; Jinyoung Lee; Hee-Jong Yang; Yong-Joon Chwae; Kyongmin Kim; Sun Park; Ho-Joon Shin
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

4.  Mitogenicity of Naegleria fowleri extract for murine T lymphocytes.

Authors:  A Ferrante; C Smyth
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

5.  The role of antibody in immunity against experimental naegleria meningoencephalitis ('amoebic meningitis').

Authors:  A Ferrante; B Rowan-Kelly
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.